The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
Open accessPublished version of a preprint
Abstract
Chimeric antigen receptor (CAR)–modified T cells with anti-CD19 specificity are a highly effective novel immune therapy for relapsed/refractory acute lymphoblastic leukemia. Cytokine release syndrome (CRS) is the most significant and life-threatening toxicity. To improve understanding of CRS, we measured cytokines and clinical biomarkers in 51 CTL019-treated patients. Peak levels of 24 cytokines, including IFNγ, IL6, sgp130, and sIL6R, in the first month after infusion were highly associated with severe CRS. Using regression modeling, we could accurately predict which patients would develop severe CRS with a signature composed of three cytokines. Results were validated in an independent cohort. Changes in serum biochemical markers, including C-reactive protein and ferritin, were associated with CRS but failed to predict development of severe CRS. These comprehensive profiling data provide novel insights into CRS biology and, importantly, represent the first data that can accurately predict which patients have a high probability of becoming critically ill. Significance: CRS is the most common severe toxicity seen after CAR T-cell treatment. We developed models that can accurately predict which patients are likely to develop severe CRS before they become critically ill, which improves understanding of CRS biology and may guide future cytokine-directed therapy. Cancer Discov; 6(6); 664–79. ©2016 AACR. See related commentary by Rouce and Heslop, p. 579. This article is highlighted in the In This Issue feature, p. 561
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most severe of these immune-related adverse events (irAEs) are cytokine release syndrome (CRS) and neurotoxicity, most prominently described in patients treated with CAR-T-cells [6–11].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Immune checkpoint blockade induces irAEs during short-term follow-up of some patients with cancer, though robust immune biomarkers correlating with adverse effects of therapy are still being investigated [1, 4, 7, 20–25].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Serum biomarkers, including glycoprotein 130 (gp130), interferon-γ, and interleukin-1–receptor antagonist (IL1RA), can be used to predict the severity of cytokine storm induced by CAR T-cell therapy”
From Cytokine storm (2020) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citationChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Self-citationChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Self-citationEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citationRose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · cited 3×
“In other IL6-mediated diseases, IL6 levels often go up and sIL6R levels either increase or decrease after treatment as the interaction between IL6R and IL6 is blocked (21, 23, 24).”
BackgroundSelf-citationBorowitz, M. J., Devidas, M., Hunger, S. P., Bowman, W. P., Carroll, A. J., Carroll, W. L., Linda, S. B., Martin, P. L., Pullen, D. J., Viswanatha, D. S., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132837 · Cited by 841
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,000
Glatiramer acetate enhances tumor retention and innate activation of immunostimulants
Pressnall, M. M., Huang, A., Groer, C. E., Huayamares, S. G., Forrest, M. L., & Berkland, C. J. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120812 · Cited by 15
Zhou, L., Fu, W., Wu, S., Xu, K., Qiu, L., Xu, Y., Yan, X., Zhang, Q., Zhang, M., Wang, L., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18873 · Cited by 15
The confused oncologic patient: a rational clinical approach
Nolan, C. P., & DeAngelis, L. M. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000392 · Cited by 15
Autoimmune complications of cancer immunotherapy
Dhodapkar, K. M. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.08.004 · Cited by 15
CAR T‑cell therapy for gastric cancer: Potential and perspective (Review)
Long, B., Qin, L., Zhang, B., Li, Q., Wang, L., Jiang, X., Ye, H., Zhang, G., Yu, Z., & Jiao, Z. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4982 · Cited by 16
Li, J., Wu, Z., & Zhao, N. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01056-8 · Cited by 15
Raju, V., Reddy, R., Javan, A. C., Hajihossainlou, B., Weissleder, R., Guiseppi‐Elie, A., Kurabayashi, K., Jones, S. A., & Faghih, R. T. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2025.108592 · Cited by 14
Yoo, K. H., Szymura, S. J., Dong, Z., Kandel, A., Cha, S.-C., & Kwak, L. W. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017873 · Cited by 14
Lack of tocilizumab effect on mortality in COVID19 patients
Holt, G. E., Batra, M., Murthi, M., Kambali, S., Santos, K., Bastidas, M. V. P., Asif, H., Haddadi, S., Arias, S., & Mirsaeidi, M. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-74328-x · Cited by 14
Bridging treatment prior to chimeric antigen receptor T‐cell therapy in multiple myeloma
Bal, S., & Costa, L. J. (2023) · British Journal of Haematology · doi:10.1111/bjh.19227 · Cited by 14
Acute kidney injury after CAR-T cell therapy: exploring clinical patterns, management, and outcomes
Vincendeau, M., Joseph, A., Thiéblemont, C., Rabian, F., Harel, S., Valade, S., & Zafrani, L. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae123 · Cited by 14
Ureshino, H., Ando, T., Kizuka, H., Kusaba, K., Sano, H., Nishioka, A., Itamura, H., Shindo, T., Kubota, Y., Kojima, K., et al. (2017) · Hematological Oncology · doi:10.1002/hon.2481 · Cited by 14
Prevention and treatment of relapse after stem cell transplantation by cellular therapies
Falkenburg, F., Ruggiero, E., Bonini, C., Porter, D., Miller, J. C., Malard, F., Mohty, M., Kröger, N. M., & Kolb, H. J. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0227-0 · Cited by 14
Self-citationAdvances and Challenges of CAR T Cells in Clinical Trials
Holzinger, A., & Abken, H. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-23765-3_3 · Cited by 14
Neurological Immunotoxicity from Cancer Treatment
Wesley, S. F., Haggiagi, A. M., Thakur, K. T., & Jager, P. L. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136716 · Cited by 15
Kambayana, G., & Rini, S. S. (2023) · Current Rheumatology Reviews · doi:10.2174/1573397119666230214103044 · Cited by 14
Ma, S., Li, H., Zhou, D., Zhang, X., Shi, M., Cao, J., Qi, Y., Xia, J., Liu, Y., Wang, X., et al. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.01.011 · Cited by 16
Using interactive platforms to encode, manage and explore immune-related adverse outcome pathways
Mazein, A., Shoaib, M. M., Alb, M., Sakellariou, C. A., Sommer, C., Sewald, K., Reiche, K., Gogesch, P., Roser, L. A., Iannazzo, S. O., et al. (2024) · Journal of Immunotoxicology · doi:10.1080/1547691x.2024.2345154 · Cited by 16
The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer
Dettorre, G. M., Patel, M., Gennari, A., Pentheroudakis, G. E., Romano, E., Cortellini, A., & Pinato, D. J. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100123 · Cited by 14
Kean, L. S. (2018) · Blood · doi:10.1182/blood-2018-02-785881 · Cited by 15
Next-generation CAR T cells to overcome current drawbacks
Lundh, S. M., Maji, S., & Melenhorst, J. J. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02923-9 · Cited by 15
Self-citationCAR T cell therapy for children with rheumatic disease: the time is now
Wobma, H., Ardoin, S. P., Bonifant, C. L., Cooper, J. C., Kim, H., Sadun, R. E., Lewandowski, L. B., Keller, M., Colbert, R. A., Edens, C., et al. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01272-3 · Cited by 13
Meyer, L. K., Lee, J. C., Rocco, J. M., & Nichols, K. E. (2025) · Haematologica · doi:10.3324/haematol.2024.286477 · Cited by 14
Chen, G. M., Jain, A., Gering, D. T., Satulovsky, J., Datta, S., Lai, P., Karar, J., Gonzalez, V. E., Alexander, K., Chew, A., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01633-7 · Cited by 13
Self-citationIn vivo CAR-cell therapy: current challenges and emerging therapeutic advances
Yang, Y.-M., Bao, B., Cao, Y.-H., Yao, J., Ding, Y.-F., Hu, Y.-Y., Fan, F., & Zhao, J. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00447-y · Cited by 13
Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice
Luskin, M. R., & DeAngelo, D. J. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0394-x · Cited by 13
A Computational Model of Cytokine Release Syndrome during CAR T‐Cell Therapy
Zhang, Z., Liu, L., Ma, C., & Chen, W. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200130 · Cited by 13
A systematic review and meta-analysis of neopterin in rheumatic diseases
Mangoni, A. A., & Zinellu, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1271383 · Cited by 13
Ren, X., Zhang, G., Li, G., & Wang, Y. (2024) · BMC Cancer · doi:10.1186/s12885-023-11753-x · Cited by 13
Ploch, W., Sadowski, K. A., Olejarz, W., & Basak, G. W. (2024) · Cancers · doi:10.3390/cancers16193339 · Cited by 13
Gouveia, G., Saateh, A., Świetlikowska, A., Scarpellini, C., Tsang, E., Altug, H., Merkx, M., Dillen, A., Leirs, K., Spasić, D., et al. (2024) · ACS Sensors · doi:10.1021/acssensors.4c02569 · Cited by 10
Understanding the molecular bridges between the drugs and immune cell
Dash, U. C., Nayak, V., Navani, H. S., Samal, R. R., Agrawal, P., Singh, A. K., Majhi, S., Mogare, D., Duttaroy, A. K., & Jena, A. B. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108805 · Cited by 13
Maganzini, N., Reschke, A., Cartwright, A. P., Gidi, Y., Thompson, I. A. P., Yee, S. C., Hariri, A. A., Dory, C., Rosenberg‐Hasson, Y., Pan, J., et al. (2025) · Advanced Materials · doi:10.1002/adma.202412613 · Cited by 13
Renninger, J. P., Kurz, L., & Stein, H. (2025) · Drug Safety · doi:10.1007/s40264-025-01538-5 · Cited by 17
Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy
Long, J. P., Prakash, R., Edelkamp, P., Knafl, M., Lionel, A. C., Nair, R. K., Ahmed, S., Strati, P., Malpica, L., Zaki, A. A., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.3455 · Cited by 13
Tang, F., Yin, L., Ge, Y., Shang, J., & Zhu, X. (2020) · Journal of International Medical Research · doi:10.1177/0300060519893496 · Cited by 13
Taştan, C., Kançağı, D. D., Turan, R. D., Yurtsever, B., Çakırsoy, D., Abanuz, S., Yılancı, M., Seyis, U., Özer, S., Mert, S., et al. (2020) · Turkish Journal of Hematology · doi:10.4274/tjh.galenos.2020.2020.0070 · Cited by 14
Selvaggio, G., Parolo, S., Bora, P., Leonardelli, L., Harrold, J. M., Mehta, K., Rock, D. A., & Marchetti, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.818641 · Cited by 13
Mann, H., & Comenzo, R. L. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s305429 · Cited by 15
CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives
Sheikh, S., Migliorini, D., & Lang, N. (2022) · Biomedicines · doi:10.3390/biomedicines10081960 · Cited by 14
Alb, M., Reiche, K., Rade, M., Sewald, K., Loskill, P., Cipriano, M., Maulana, T. I., van der Meer, A. D., Weener, H. J., Clerbaux, L., et al. (2024) · Journal of Immunotoxicology · doi:10.1080/1547691x.2024.2345158 · Cited by 14
Wieduwilt, M. J. (2017) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2017.07.001 · Cited by 13
Zhang, M., Long, X., Xiao, Y., Jin, J., Chen, C., Meng, J., Liu, W., Liu, A., & Chen, L. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007790 · Cited by 13
CD8+ T cell-based immunotherapy: Promising frontier in human diseases
Ton, N. Q. C., Deka, G., & Park, P. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116909 · Cited by 12
Galán‐Gómez, V., González‐Martínez, B., Alonso‐Saladrigues, A., Rives, S., Herrero, B., Kwon, M., Sánchez‐Pina, J. M., Minguillón, J., Martínez-Romera, I., Aguilar, I. M., et al. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00638-3 · Cited by 12
Venous Thromboembolic Events in Cancer Immunotherapy: A Narrative Review
Fowler, C., & Pastores, S. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14144926 · Cited by 12
Yang, S., Wang, W., Rao, Q., Xu, Y., Zhang, S., Qu, Y., Zhuang, Q.-C., Mao, J., Sun, L., Geng, D., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012331 · Cited by 12
Banerjee, R. K., Fakhri, B., & Shah, N. D. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1924370 · Cited by 12
A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies
Newman, H. M., & Teachey, D. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158600 · Cited by 12
Self-citationT cell‐dependent bispecific antibodies alter organ‐specific endothelial cell–T cell interaction
Himmels, P., Nguyen, T. T. T., Caunt, M., Arrazate, A., Yeung, S., Burton, J., Clark, R., Tótpál, K., Jesudason, R., Yang, Y. A., et al. (2023) · EMBO Reports · doi:10.15252/embr.202255532 · Cited by 12
Dey, S., Devender, M., Rani, S., & Pandey, R. K. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.02.003 · Cited by 12
CAR T-Cell Therapy Effects: Review of Procedures and Patient Education
McConville, H., Harvey, M., Callahan, C. A., Motley, L. S., Difilippo, H., & White, C. (2017) · Clinical journal of oncology nursing · doi:10.1188/17.cjon.e79-e86 · Cited by 12
Self-citationTisagenlecleucel-T for the treatment of acute lymphocytic leukemia
Thomas, X., & Paubelle, É. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1533951 · Cited by 12
Chimeric antigen receptor T‐cell therapy in patients with neurologic comorbidities
Rubinstein, J. D., Nelson, A. S., Krupski, C., O'Brien, W., Taylor, J. M., Badgett, T. C., Huang, M. A., Davies, S. M., & Phillips, C. L. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28199 · Cited by 12
Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer
Xu, C., Ju, D., & Zhang, X. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac006 · Cited by 13
Sepiashvili, L., Alli, Z., Bohn, M. K., Hall, A., Karin, A., Murata, K., & Adeli, K. (2021) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2021.09.004 · Cited by 11
Toxicities of CAR T-cell therapy: a review of current literature
Asghar, M. S., Shah, S. M. I., Rani, A., Kazmi, S., Savul, I. S., Ukrani, J. D., Khan, F., Hasan, C. A., Rathore, N., Syed, M., et al. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001375 · Cited by 11
Yang, Y., Luo, K., & Xu, G. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110311 · Cited by 13
Acute T-cell lymphoblastic leukemia: chimeric antigen receptor technology may offer a new hope
Jing, J., Ma, Y., Xie, Z., Wang, B., Chen, Y., Chi, E., Wang, J., Zhang, K., Wang, Z., & Li, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1410519 · Cited by 13
Jain, M. D., Abramson, J. S., & Ansell, S. M. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473916 · Cited by 11
T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis
Zaïr, Z. M., Butterworth, G., Shalaby, M., Oštarijaš, E., & Thisthlethwaite, F. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102991 · Cited by 11
CAR-T therapy for leukemia: progress and challenges
Wang, X., Xiao, Q., Wang, Z., & Feng, W. (2016) · Translational research · doi:10.1016/j.trsl.2016.10.008 · Cited by 11
Driving the CAR to the Bone Marrow Transplant Program
Dave, H., Jerkins, L. P., Hanley, P. J., Bollard, C. M., & Jacobsohn, D. A. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00544-6 · Cited by 11
Campbell, C. M., Guha, A., Haque, T. Z., Neilan, T. G., & Addison, D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092935 · Cited by 11
Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies
Gutiérrez, C., Rajendram, P., & Pastores, S. M. (2020) · Critical Care Clinics · doi:10.1016/j.ccc.2020.08.003 · Cited by 12
Rubio, M., Varlet, P., Allain, V., Ballot, C., Cuffel, A., Deschamps, M., Ferrand, C., Foguenne, J., Forcade, É., Huynh, A., et al. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.04.008 · Cited by 12
Tan, J. Y., Low, M. H., Chen, Y., & Lim, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136931 · Cited by 12
Khalid, F., Gupta, R., Gor, R., Gor, D., Singh, V., & Eltoukhy, H. S. (2023) · World Journal of Oncology · doi:10.14740/wjon1575 · Cited by 11
Ding, L., Hu, Y., Zhao, K., Wei, G., Wu, W., Wu, Z., Xiao, L., & Huang, H. (2018) · Medicine · doi:10.1097/md.0000000000009992 · Cited by 11
At the end of the beginning: immunotherapies as living drugs
Feigal, E. G., DeWitt, N. D., Cantilena, C., Peck, C. C., & Stroncek, D. (2019) · Nature Immunology · doi:10.1038/s41590-019-0452-8 · Cited by 11
Podoplanin as an Attractive Target of CAR T Cell Therapy
Waseda, M., & Kaneko, S. (2020) · Cells · doi:10.3390/cells9091971 · Cited by 11
Chen, W., Wang, Y., Qi, K., Shi, M., Cao, J., Bhansali, R. S., Wang, X., Liu, Y., Li, H., Zhang, H.-X., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2020.12.017 · Cited by 11
Laetsch, T. W., Yanik, G. A., Boyer, M. W., & Rheingold, S. R. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100848 · Cited by 12
Self-citationIL-6 Blockade in Cytokine Storm Syndromes
Barrett, D. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-22094-5_32 · Cited by 11
Self-citationOmotesho, Q. A., Escamilla, A., Pérez-Ruiz, E., Frecha, C. A., Rueda‐Domínguez, A., & Barragán, I. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1348156 · Cited by 10
Xi, X., Yan, X., Chen, Y., Li, W., Dong, J., Ou, X., & Tan, H. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2385489 · Cited by 10
Grégoire, C., de Oliveira, B. C., Caimi, P. F., Caers, J., & Melenhorst, J. J. (2024) · British Journal of Haematology · doi:10.1111/bjh.19751 · Cited by 12
Self-citationAdoptive cell therapy for cancer: combination strategies and biomarkers
Liu, S., Jiang, W., Sheng, J., Wang, L., & Cui, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1603792 · Cited by 10
How I treat HLH-like toxicities after immune effector cell therapy
Johnson, W. T., McNerney, K. O., Frank, M. J., & Shah, N. N. (2026) · Blood · doi:10.1182/blood.2025032352 · Cited by 10
Forecasting Cytokine Storms with New Predictive Biomarkers
Rouce, R. H., & Heslop, H. E. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0493 · Cited by 10
Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia
Freyer, C. W. (2018) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2018.9.5.8 · Cited by 10
Neurotoxicities After CAR T-Cell Immunotherapy
Gust, J., Ceppi, F., & Turtle, C. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66181-2.00007-x · Cited by 10
A brief overview of SARS-CoV-2 infection and its management strategies: a recent update
Das, A., Pathak, S., Premkumar, M., Sarpparajan, C. V., Balaji, E., Duttaroy, A. K., & Banerjee, A. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04848-3 · Cited by 10
Flerlage, T., Fan, K., Qin, Y., Agulnik, A., Arias, A. V., Cheng, C., Elbahlawan, L. M., Ghafoor, S., Hurley, C., McArthur, J. A., et al. (2023) · Critical Care Explorations · doi:10.1097/cce.0000000000000976 · Cited by 10
Shalaby, N., Xia, Y., Kelly, J. J., Sanchez‐Pupo, R. E., Martínez, F. M., Fox, M. S., Thiessen, J. D., Hicks, J. W., Scholl, T. J., & Ronald, J. A. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06722-w · Cited by 10
Patton, L., Monteith, B. E., Heffernan, P., Herzinger, T., & Wilson, B. E. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1394543 · Cited by 12
A Model-Based Investigation of Cytokine Storm for T-Cell Therapy
Hopkins, B., Tucker, M., Pan, Y., Fang, N., & Huang, Z. J. (2018) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2018.09.039 · Cited by 10
Lundh, S. M., Jung, I.-Y., Dimitri, A. J., Vora, A., Melenhorst, J. J., Jadlowsky, J. K., & Fraietta, J. A. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00628-1 · Cited by 10
Self-citationAdvances in Supportive Care for Acute Lymphoblastic Leukemia
Cook, J., & Litzow, M. R. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00585-2 · Cited by 11
Márquez, C. P., Montiel-Esparza, R., Hui, C., Schultz, L. M., Davis, K. L., Hoppe, R. T., Donaldson, S. S., Ramakrishna, S., & Hiniker, S. M. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28870 · Cited by 10
Taking a BiTE out of the CAR T space race
Patel, A., Oluwole, O. O., Savani, B. N., & Dholaria, B. (2021) · British Journal of Haematology · doi:10.1111/bjh.17622 · Cited by 10
Browne, E. K., Daut, E., Hente, M., Turner, K., Waters, K., & Duffy, E. A. (2021) · Journal of Pediatric Oncology Nursing · doi:10.1177/10434542211040203 · Cited by 10
Chimeric Antigen Receptor T-cell Therapy
Talleur, A. C., Myers, R. M., Annesley, C., & Shalabi, H. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.03.005 · Cited by 11
Use of Chimeric Antigen Receptor T Cells in Allogeneic Hematopoietic Stem Cell Transplantation
Li, J., Zhang, X., Zhong, J. F., & Zhang, C. (2018) · Immunotherapy · doi:10.2217/imt-2018-0089 · Cited by 10
Migliorini, D., Mason, N. J., & Posey, A. D. (2018) · ILAR Journal · doi:10.1093/ilar/ilz009 · Cited by 12
Are all cytokine storms the same?
Panoskaltsis, N. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02822-2 · Cited by 11
Rejuvenation Strategy for Inducing and Enhancing Autoimmune Response to Eliminate Senescent Cells
Wang, X., Zhang, C., Su, J., Ren, S., Wang, X., Zhang, Y., Yuan, Z., He, X., Wu, X., Li, M., et al. (2025) · Aging and disease · doi:10.14336/ad.2024.0579 · Cited by 8
Zhang, X., Yang, Y. B., Zhang, P., Wang, Y., & Shen, F. (2024) · Future Science OA · doi:10.1080/20565623.2024.2422786 · Cited by 9
Hemophagocytic lymphohistiocytosis post chimeric antigen receptor T cell therapies
Wang, J., Jiang, H., Zhang, Y., Hu, Y., & Mei, H. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2444673 · Cited by 9
Emerging Strategies of Cell and Gene Therapy Targeting Tumor Immune Microenvironment
Wang, R., Duan, X., Li, J., Zhang, C., & Shen, L. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-4308 · Cited by 10
Metadata
- Authors
- Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., Barrett, D. M., Weiss, S. L., Fitzgerald, J. C., Berg, R. A., Aplenc, R., Callahan, C., Rheingold, S. R., Zheng, Z., Rose-John, S., White, J. C., Nazimuddin, F., Wertheim, G., Levine, B. L., June, C. H., Porter, D. L., & Grupp, S. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- University of Pennsylvania (US)
- 10Institute of Biochemistry, CAU Kiel, Germany.
- Alexander T. Augusta Military Medical Center (US)
- Corresponding author
- Teachey, David T.
- ORCID
- Teachey, David T.
- Lacey, Simon F.
- Shaw, Pamela A.
- Melenhorst, J. Joseph
- Maude, Shannon L.
- Frey, Noelle
- Gonzalez, Vanessa E.
- Chen, Fang
- Barrett, David M.
- Weiss, Scott L.
- Fitzgerald, Julie C.
- Berg, Robert A.
- Aplenc, Richard
- Callahan, Colleen
- Rheingold, Susan R.
- Zheng, Zhaohui
- Wertheim, Gerald
- Levine, Bruce L.
- June, Carl H.
- Porter, David L.
- Grupp, Stephan A.
- Venue
- Cancer Discovery
- Published
- 2016-06-01
- Volume
- 6
- Issue
- 6
- Pages
- 664-679
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5448406
- OpenAlex
- W2340435799
- Cited by
- 1,102
- References
- 35
- Citations by year
- 2026: 72 · 2025: 116 · 2024: 94 · 2023: 110 · 2022: 102 · 2021: 142 · 2020: 181 · 2019: 103 · 2018: 93 · 2017: 64 · 2016: 22
- FWCI
- 50.70
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA165206, R01CA102646, R01CA116660, R01CA193776, P30CA016520)
- National Institute of General Medical Sciences (K23GM110496)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cytokine release syndrome, CAR T-cell therapy, acute lymphoblastic leukemia, CD19 CAR T cells, tisagenlecleucel, predictive biomarkers, cytokine profiling, interferon-gamma, interleukin-6, soluble gp130, C-reactive protein, ferritin, relapsed/refractory leukemia, toxicity prediction
- MeSH terms
- Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Immunotherapy, Male, Middle Aged, Phenotype, Prognosis, Receptors, Antigen, T-Cell, ROC Curve, Severity of Illness Index, Tumor Lysis Syndrome, Biomarkers, Cytokines, Treatment Outcome, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Antibodies, Monoclonal, Humanized, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
